Stockreport

Why Analysts Are Rewriting Esperion's Story After New Pipeline Results and Global Partnerships [Yahoo! Finance]

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF Esperion Therapeutics has recently seen a slight increase in its fair value target, moving from $6.10 to $6.15 per share following adjustments to analysts' expectations. [Read more]